Innovent Biologics (STU:6IB) Retained Earnings: €-1,830 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6IB Innovent Biologics Inc STU:6IB
80 GF Score
Price €10.10
GF Value €11.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Retained Earnings?

Innovent Biologics STU:6IB +4.21% 80 Retained Earnings is €-1,830 Mil as of Dec. 2025. GuruFocus rates STU:6IB with a GF Score™ of 80/100 and a GF Value™ of €11.08 (Fairly Valued). The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Innovent Biologics's retained earnings for the quarter that ended in Dec. 2025 was €-1,830 Mil.

Innovent Biologics's quarterly retained earnings increased from Dec. 2024 (€-2,086 Mil) to Jun. 2025 (€-1,820 Mil) but then declined from Jun. 2025 (€-1,820 Mil) to Dec. 2025 (€-1,830 Mil).

Innovent Biologics's annual retained earnings declined from Dec. 2023 (€-2,025 Mil) to Dec. 2024 (€-2,086 Mil) but then increased from Dec. 2024 (€-2,086 Mil) to Dec. 2025 (€-1,830 Mil).


Innovent Biologics  (STU:6IB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Innovent Biologics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Innovent Biologics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics Retained Earnings Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1,995.82 -2,024.99 -2,086.42 -1,830.03

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,024.99 -2,069.39 -2,086.42 -1,819.88 -1,830.03
STU:6IB
80GF Score
Innovent Biologics Inc STU:6IB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovent Biologics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-1,830 Mil mean?
Innovent Biologics (STU:6IB) has a Retained Earnings of €-1,830 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Innovent Biologics and its competitors.
Is Innovent Biologics' Retained Earnings too high?
Innovent Biologics' current Retained Earnings is €-1,830 Mil. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Retained Earnings compare to VRTX and REGN?
Innovent Biologics' Retained Earnings of €-1,830 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current Retained Earnings is €-1,830 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Fairly Valued. The stock's GF Value™ is €11.08, compared to a current price of €10.10 — trading 8.8% below its estimated fair value. The current Retained Earnings is €-1,830 Mil. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current Retained Earnings is €-1,830 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innovent Biologics (STU:6IB) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of €10.10 is trading 8.8% below its estimated GF Value™ of €11.08. GuruFocus considers Innovent Biologics to be Fairly Valued.

Key valuation signals for STU:6IB:

  • Retained Earnings: €-1,830 Mil
  • GF Value™: €11.08 vs. price of €10.10 (8.8% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score

Get the complete analysis for STU:6IB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.10
Price
€11.08
GF Value